We are proud to announce that our brand-new penicillin Powders for solution for injection/infusion production
facility in Vietnam has been completed, with the EU GMP certificate issued July 5th, 2024. The facility which will perform the aseptic filling, packaging and quality control of the vials complies with the recently introduced Annex 1 GMP requirements. Batch release for European markets will take place at our Cyprus site.
Medochemie boasts more than three decades of manufacturing expertise in penicillin dry vials at our Cyprus facility. Products currently being manufactured in Cyprus include Amoxicillin, Ampicillin, Cloxacillin, Flucloxacillin, Amoxicillin/Clavulanic acid and Piperacillin/Tazobactam. We have successfully finalised DCP procedures in Marketing Authorisations for business partners in several countries including Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Norway, Poland, Sweden & Switzerland.
Medochemie would like to express its appreciation to the management and staff of its Vietnamese wholly owned subsidiary as well as to key executives of the Cyprus holding for their support and coordination resulting in a successful project materialization. We also thank the key suppliers of the main equipment of the facility, IMA Industria Macchine Automatische S.p.A, Marchesini Group S.p.A and Fedegari Autoclavi S.p.A from Italy, for their support and on time cooperation.
Our green field production facility in Vietnam will bank on this extensive experience and, in addition to the technology transfer of the above products, will develop other combination products as well as additional older penicillin molecules.
If you are facing Annex I challenges, considering an alternative CMO or seeking to expand your portfolio with additional injectable penicillin molecules, please contact:
Mr. Gregory Charitonos
Director
Medochemie (Far East) Ltd
gregory.charitonos@medochemie.com
OR
Andreas Loizou
Group Business Development Director
Medochemie Ltd
andreas.loizou@medochemie.com